CHMP party conditionally approves CTI's Pixuvri: also OKs GSK's Nimenrix, Prostrakan's Sancuso
This article was originally published in Scrip
Executive Summary
The Committee for Human Medicinal Products (CHMP) has announced the outcomes of its 13-16 February 2012 deliberations, recommending the approval of GlaxoSmithKline meningococcal vaccine, Nimenrix (scripintelligence.com, 17 February 2012), and Prostrakan’s adjunct antinausea patch Sancuso (granisetron; scripintelligence.com, 17 February 2012).
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.